Prostaglandin production in cirrhosis and portal hypertension - Experimental and clinical study

Hepatology Research

Volumn 10, Issue 2, 1998, Pages 131-141

  Ohnishi, Akihiro ^a   Harada, Makoto ^a   Matsuo, Atsushi ^a   Kawai, Bunpei ^a   Kunihiro, Naoko ^a   Tada, Yoshiki ^a   Chau, Tommy ^a   Koizumi, Fumiaki ^a   Tanaka, Teruji ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

6 keto prostaglandin F1 ; Liver cirrhosis; Portal hypertension; Prostaglandin; Thromboxane B2

Indexed keywords

6 OXOPROSTAGLANDIN F1 ALPHA; CARBON TETRACHLORIDE; PROSTAGLANDIN; THROMBOXANE B2;

ADULT; ANIMAL MODEL; ARTICLE; BLEEDING; CHRONIC LIVER DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; HUMAN; LIVER CIRRHOSIS; MALE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PRIORITY JOURNAL; PROSTAGLANDIN METABOLISM; PROSTAGLANDIN SYNTHESIS; RAT;

EID: 0032007782     PISSN: 09284346     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Ballard H.S., Marcus A.J. Platelet aggregation in portal cirrhosis. Arch Intern Med. 136:1976;316-319.
2. Thomas D.P., Ream V.J., Stuart R.K. Platelet aggregation in patients with Lannec's cirrhosis of the liver. New Engl J Med. 276:1967;134-138.
3. Owen J.S., Hutton R.A., Day R.C., Bruckdorfer K.R., McIntyre N. Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res. 22:1981;423-430.
4. 2 and prostacyclin. Pharmacol Rev. 30:1979;293-331.
5. Ohnishi A., Ishizaki T., Echizen H. et al. Effects of sustained thromboxane synthase inhibition on exercise-induced changes in eicosanoid formation, catecholamine concentration, and platelet aggregation in humans. Clin Pharmacol Ther. 51:1992;454-464.
6. Reichen J. Liver function and pharmacological considerations in pathogenesis and treatment of portal hypertension. Hepatology. 11:1990;1066-1078.
7. Benoit J.N., Granger D.N. Splanchnic hemodynamics in chronic portal hypertension. Semin Liver Dis. 6:1986;287-297.
8. Oberti F., Sogni P., Cailmail S., Moreau R., Pipy B., Lebrec D. Role of prostacyclin in hemodynamic alterations in conscious rats with extrahepatic or intrahepatic portal hypertension. Hepatology. 18:1993;621-627.
9. Bruix J., Bosch J., Kravetz D. Effect of prostaglandin inhibition on systemic and hepatic hemodynamics in patients with cirrhosis of the liver. Gastroenterology. 88:1985;430-435.
10. Wernze H., Tittor W., Goerig M. Release of prostanoids into the portal and hepatic vein in patients with chronic liver disease. Hepatology. 6:1986;911-916.
11. Ohnishi A., Murakami S., Harada M. et al. Renal and hormonal responses to repeated treatment with enalapril in non-aztemic cirrhosis with ascites. J Hepatol. 20:1994;223-230.
12. Sitzmann J.V., Bulkley G.B., Mitchell M.C., Campbell K. Role of prostacyclin in the splanchnic hyperemia contributing to portal hypertension. Ann Surg. 209:1989;322-327.
13. Hamilton G., Phing R.C.F., Hutton R.A., Dandona P., Hobbs K.E.F. The relationship between prostacyclin activity and pressure in the portal vein. Hepatology. 2:1982;236-242.
14. Hamilton G., Rosza I., Hutton R., Chow F.P.R., Dandona P., Hobbs K.E.F. Portal vein prostacyclin activity in experimental portal hypertension in rats. Clin Sci. 60:1981;327-329.
15. Hashizume M., Inokuchi K., Tanaka K. The role of prostacyclin in patients with portal hypertension. Liver. 5:1985;89-93.
16. Sitzmann J.V., Li S., Atkinson N.F. Evidence for role of prostacyclin as a systemic hormone in portal hypertension. Surgery. 109:1991;149-153.
17. Sitzmann J.V., Campbell K., Wu Y., Clair C.S. Prostacyclin production in acute, chronic, and long-term experimental portal hypertension. Surgery. 115:1994;290-294.
18. Lin P.W., Shan Y.S. Portal hemodynamics and humoral factors involved in a portal hypertensive rabbit model. Proc Natl Sci Counc. 19:1995;240-245.